|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CAP1 |
Gene summary for CAP1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CAP1 | Gene ID | 10487 |
| Gene name | cyclase associated actin cytoskeleton regulatory protein 1 | |
| Gene Alias | CAP | |
| Cytomap | 1p34.2 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | D3DPU2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10487 | CAP1 | HTA11_2487_2000001011 | Human | Colorectum | SER | 4.97e-13 | 9.95e-01 | -0.1808 |
| 10487 | CAP1 | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.24e-15 | 8.83e-01 | -0.0811 |
| 10487 | CAP1 | HTA11_78_2000001011 | Human | Colorectum | AD | 1.54e-25 | 1.06e+00 | -0.1088 |
| 10487 | CAP1 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.36e-35 | 1.07e+00 | -0.1954 |
| 10487 | CAP1 | HTA11_411_2000001011 | Human | Colorectum | SER | 2.46e-08 | 1.44e+00 | -0.2602 |
| 10487 | CAP1 | HTA11_2112_2000001011 | Human | Colorectum | SER | 1.43e-03 | 9.67e-01 | -0.2196 |
| 10487 | CAP1 | HTA11_83_2000001011 | Human | Colorectum | SER | 6.56e-05 | 6.83e-01 | -0.1526 |
| 10487 | CAP1 | HTA11_696_2000001011 | Human | Colorectum | AD | 8.52e-11 | 5.50e-01 | -0.1464 |
| 10487 | CAP1 | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.06e-13 | 7.98e-01 | -0.059 |
| 10487 | CAP1 | HTA11_2992_2000001011 | Human | Colorectum | SER | 1.70e-04 | 9.66e-01 | -0.1706 |
| 10487 | CAP1 | HTA11_5212_2000001011 | Human | Colorectum | AD | 7.13e-13 | 1.19e+00 | -0.2061 |
| 10487 | CAP1 | HTA11_7663_2000001011 | Human | Colorectum | SER | 1.01e-02 | 2.97e-01 | 0.0131 |
| 10487 | CAP1 | HTA11_6801_2000001011 | Human | Colorectum | SER | 1.85e-05 | 9.29e-01 | 0.0171 |
| 10487 | CAP1 | HTA11_7696_3000711011 | Human | Colorectum | AD | 3.57e-03 | 2.90e-01 | 0.0674 |
| 10487 | CAP1 | HTA11_6818_2000001021 | Human | Colorectum | AD | 2.65e-05 | 4.98e-01 | 0.0588 |
| 10487 | CAP1 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 4.74e-13 | 5.84e-01 | 0.294 |
| 10487 | CAP1 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 4.35e-02 | 1.01e+00 | 0.3487 |
| 10487 | CAP1 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 1.32e-19 | 1.09e+00 | 0.281 |
| 10487 | CAP1 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 6.06e-29 | 9.28e-01 | 0.3859 |
| 10487 | CAP1 | A015-C-203 | Human | Colorectum | FAP | 2.10e-03 | -1.24e-01 | -0.1294 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0007163 | Colorectum | AD | establishment or maintenance of cell polarity | 77/3918 | 218/18723 | 5.72e-07 | 2.08e-05 | 77 |
| GO:0001667 | Colorectum | AD | ameboidal-type cell migration | 137/3918 | 475/18723 | 2.17e-05 | 4.33e-04 | 137 |
| GO:0006898 | Colorectum | AD | receptor-mediated endocytosis | 76/3918 | 244/18723 | 1.07e-04 | 1.59e-03 | 76 |
| GO:00071631 | Colorectum | SER | establishment or maintenance of cell polarity | 60/2897 | 218/18723 | 3.45e-06 | 1.33e-04 | 60 |
| GO:00016671 | Colorectum | SER | ameboidal-type cell migration | 105/2897 | 475/18723 | 6.97e-05 | 1.59e-03 | 105 |
| GO:00071632 | Colorectum | MSS | establishment or maintenance of cell polarity | 72/3467 | 218/18723 | 1.90e-07 | 8.30e-06 | 72 |
| GO:00068981 | Colorectum | MSS | receptor-mediated endocytosis | 69/3467 | 244/18723 | 1.18e-04 | 1.82e-03 | 69 |
| GO:00016672 | Colorectum | MSS | ameboidal-type cell migration | 120/3467 | 475/18723 | 1.37e-04 | 2.05e-03 | 120 |
| GO:00071633 | Colorectum | FAP | establishment or maintenance of cell polarity | 64/2622 | 218/18723 | 2.83e-09 | 5.07e-07 | 64 |
| GO:00068982 | Colorectum | FAP | receptor-mediated endocytosis | 62/2622 | 244/18723 | 1.47e-06 | 6.39e-05 | 62 |
| GO:00016673 | Colorectum | FAP | ameboidal-type cell migration | 100/2622 | 475/18723 | 1.42e-05 | 3.79e-04 | 100 |
| GO:000716320 | Esophagus | ESCC | establishment or maintenance of cell polarity | 143/8552 | 218/18723 | 2.05e-09 | 4.65e-08 | 143 |
| GO:000689818 | Esophagus | ESCC | receptor-mediated endocytosis | 142/8552 | 244/18723 | 5.22e-05 | 4.05e-04 | 142 |
| GO:000166720 | Esophagus | ESCC | ameboidal-type cell migration | 250/8552 | 475/18723 | 1.22e-03 | 5.97e-03 | 250 |
| GO:000689811 | Liver | Cirrhotic | receptor-mediated endocytosis | 91/4634 | 244/18723 | 8.13e-06 | 1.22e-04 | 91 |
| GO:000716312 | Liver | Cirrhotic | establishment or maintenance of cell polarity | 82/4634 | 218/18723 | 1.55e-05 | 2.11e-04 | 82 |
| GO:000166712 | Liver | Cirrhotic | ameboidal-type cell migration | 145/4634 | 475/18723 | 2.23e-03 | 1.36e-02 | 145 |
| GO:000716322 | Liver | HCC | establishment or maintenance of cell polarity | 133/7958 | 218/18723 | 2.48e-08 | 5.73e-07 | 133 |
| GO:000689821 | Liver | HCC | receptor-mediated endocytosis | 134/7958 | 244/18723 | 5.73e-05 | 5.31e-04 | 134 |
| GO:000166721 | Liver | HCC | ameboidal-type cell migration | 226/7958 | 475/18723 | 1.35e-02 | 4.81e-02 | 226 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| RETN | CAP1 | RETN_CAP1 | RESISTIN | Breast | DCIS |
| RETN | CAP1 | RETN_CAP1 | RESISTIN | Cervix | Precancer |
| RETN | CAP1 | RETN_CAP1 | RESISTIN | Endometrium | ADJ |
| RETN | CAP1 | RETN_CAP1 | RESISTIN | Endometrium | AEH |
| RETN | CAP1 | RETN_CAP1 | RESISTIN | Endometrium | Healthy |
| RETN | CAP1 | RETN_CAP1 | RESISTIN | HNSCC | OSCC |
| RETN | CAP1 | RETN_CAP1 | RESISTIN | Lung | AAH |
| RETN | CAP1 | RETN_CAP1 | RESISTIN | Lung | ADJ |
| RETN | CAP1 | RETN_CAP1 | RESISTIN | Lung | AIS |
| RETN | CAP1 | RETN_CAP1 | RESISTIN | Lung | Healthy |
| RETN | CAP1 | RETN_CAP1 | RESISTIN | Lung | IAC |
| RETN | CAP1 | RETN_CAP1 | RESISTIN | Lung | MIAC |
| RETN | CAP1 | RETN_CAP1 | RESISTIN | Lung | Precancer |
| RETN | CAP1 | RETN_CAP1 | RESISTIN | Prostate | Healthy |
| RETN | CAP1 | RETN_CAP1 | RESISTIN | Skin | ADJ |
| RETN | CAP1 | RETN_CAP1 | RESISTIN | THCA | Cancer |
| RETN | CAP1 | RETN_CAP1 | RESISTIN | THCA | PTC |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CAP1 | SNV | Missense_Mutation | c.498N>G | p.Asn166Lys | p.N166K | Q01518 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-D8-A143-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| CAP1 | SNV | Missense_Mutation | rs575446557 | c.761N>A | p.Arg254His | p.R254H | Q01518 | protein_coding | tolerated(0.1) | benign(0.052) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
| CAP1 | SNV | Missense_Mutation | c.1198N>G | p.Gln400Glu | p.Q400E | Q01518 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| CAP1 | SNV | Missense_Mutation | novel | c.1358N>C | p.Val453Ala | p.V453A | Q01518 | protein_coding | deleterious(0) | possibly_damaging(0.849) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| CAP1 | SNV | Missense_Mutation | c.611G>A | p.Gly204Glu | p.G204E | Q01518 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| CAP1 | insertion | In_Frame_Ins | novel | c.364_365insTACAAGAAAAGATTC | p.Asn122delinsIleGlnGluLysIleHis | p.N122delinsIQEKIH | Q01518 | protein_coding | TCGA-AM-5820-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| CAP1 | SNV | Missense_Mutation | novel | c.1299N>T | p.Lys433Asn | p.K433N | Q01518 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-A5-A0R9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CAP1 | SNV | Missense_Mutation | novel | c.1266N>T | p.Lys422Asn | p.K422N | Q01518 | protein_coding | tolerated(0.06) | possibly_damaging(0.664) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CAP1 | SNV | Missense_Mutation | novel | c.406N>A | p.Glu136Lys | p.E136K | Q01518 | protein_coding | deleterious(0) | possibly_damaging(0.612) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CAP1 | SNV | Missense_Mutation | rs749520906 | c.600C>A | p.Phe200Leu | p.F200L | Q01518 | protein_coding | deleterious(0.03) | benign(0.001) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |